“Global Clinical Trial Supply and Logistics Market for Pharma set to grow to $15bn by 2025” says new Visiongain report

24 April 2020
Pharma

Visiongain has launched a new pharma report Clinical Trial Supply and Logistics Market for Pharma: Forecasts by Type (Clinical Trial Manufacturing (Clinical Trial Packaging, Others), Clinical Trial Logistics and Distribution (Clinical Trial Cold Chain Logistics, Others), Clinical Trial Supply Chain Management), by End Users (CRO’s, Pharma & Biotech, Others (Academics, Research Institutes etc.)) PLUS COVID-19 Impact Analysis.

Demands for increasingly complex and expensive clinical trials have led drug developers to look to external service providers to source clinical trial materials and deliver them to investigator sites. Demand for biological and orphan drugs will be one of the factors that drive the clinical trial supply and logistics market for pharma. Rising need for cold chain logistics will increase demand for new packaging and monitoring technologies that offer lower-cost solutions, including reusable packaging and phase change materials that allow cooling for more-specific temperature ranges.

The lead analyst of the report commented "The outbreak of COVID-19 has impacted the clinical trials industry causing delays to the 336,444 clinical trials listed on the Clinical Trials website. The impact of COVID-19 has shifted the focus of biopharmaceutical companies to developing a vaccine for COVID-19 and thus potentially disrupting clinical trials for other diseases.

As the pandemic increases the demand for more effective pharmaceutical and medical products will rise. This requires clinical trial supply and logistic service providers to work closely with their end users and safeguard against clinical supply disruptions. Visiongain anticipates that this will create new opportunities for the market players in order to utilise on demand warehousing with the outsourced workforce for value addition & order fulfilment."

Leading companies featured in the report include Almac Group, Amatsigroup, Catalent, DHL, FedEx, Fisher Clinical Services, Marken. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever